iBio, Inc.
NASDAQ:IBIOBiotechnology
+$0.00 today
- Market cap
- $59.75M
- Beta
- 1.29
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.81M
IBIO Interest Expense
Cost of servicing the company's debt during the period.
iBio, Inc.NASDAQ: IBIO
Interest Expense · Q4 FY2026 · quarter ended Jun 2026
Interest expense turns negative
Q4 FY2026 interest expense was -$46K, compared with $44K a year earlier. Trailing-twelve-month interest expense was $53K. Over 3 fiscal years it compounded at -13.9% a year.
Context
- Interest expense amounted to 53.0% of revenue in FY2026, unchanged from a year earlier.
- Interest expense increased in 2 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest expense holds near -$46K or moves back toward the trailing-twelve-month quarterly average of $13.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2026
- 53K USD
- Year-over-year change
- -75.0%
- 4-year CAGR
- -56.0%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 53K | -75.0% |
| FY2025 | 2025-06-30 | 212K | +23.3% |
| FY2024 | 2024-06-30 | 172K | +107.2% |
| FY2023 | 2023-06-30 | 83K | -94.1% |
| FY2022 | 2022-06-30 | 1.41M | — |
Interest Expense vs competitors
How IBIO compares with its peers on the latest reported figures
- IBIO's LTM Jun 2026 interest expense of $53K is the highest of the 4 companies compared; the peer median is $0.
- Interest expense amounts to 53.0% of revenue for IBIO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $53K | -75.0% | -13.9% | 53.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding IBIO) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.88M | 0 | 225K | 400K | 100K |
| Cost of Revenue | 3.79M | 0 | 0 | 0 | 0 |
| Gross Profit | (1.91M) | 0 | 225K | 400K | 100K |
| Gross Margin | -101.2% | — | 100.0% | 100.0% | 100.0% |
| Research & Development | 9.83M | 10.33M | 5.19M | 8.31M | 19.64M |
| Selling, General & Admin | 17.96M | 18.45M | 11.67M | 10.69M | 10.6M |
| Operating Expenses | 27.79M | 29.34M | 16.86M | 19M | 35.24M |
| Depreciation & Amortization | 3.79M | 1.38M | 1.25M | 1.13M | 646K |
| EBITDA | (25.72M) | (27.85M) | (14.02M) | (17.04M) | (32.35M) |
| EBITDA Margin | -1365.3% | — | -6231.6% | -4259.8% | -32345.0% |
| Operating Income | (29.7M) | (29.34M) | (16.63M) | (18.6M) | (35.14M) |
| Operating Margin | -1576.3% | — | -7392.9% | -4650.5% | -35141.0% |
| Interest Income | 177K | 213K | 363K | 437K | 2.15M |
| Interest Expense | 1.41M | 83K | 172K | 212K | 53K |
| Other Income / Expenses | 184K | 32K | 1.19M | 225K | 2.1M |
| Income Before Tax | (29.51M) | (29.31M) | (15.44M) | (18.38M) | (33.04M) |
| Pre-Tax Margin | -1566.5% | — | -6863.6% | -4594.3% | -33044.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.39M) | (65.01M) | (24.91M) | (18.38M) | (33.04M) |
| Net Margin | -2674.7% | — | -11069.8% | -4594.3% | -33044.0% |
| EPS (Basic) | (2,889.06) | (106.18) | (6.50) | (1.75) | (0.32) |
| EPS (Diluted) | (2,889.06) | (106.18) | (6.50) | (1.75) | (0.32) |
| Weighted Avg Shares | 17.44K | 612.25K | 3.83M | 10.5M | 104.06M |
| Weighted Avg Shares (Diluted) | 17.44K | 612.25K | 3.83M | 10.5M | 104.06M |
iBio, Inc.
NASDAQ:IBIO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.